SPOTLIGHT -
EP. 1: Triggers to Initiate Androgen-Deprivation Therapy (ADT) in Prostate Cancer
EP. 2: Advanced Imaging Techniques for Prostate Cancer
EP. 3: Intermittent versus Continuous Androgen-Deprivation Therapy in Prostate Cancer
EP. 4: Multidisciplinary Approach and Role of PSA and Testosterone Monitoring in Prostate Cancer
EP. 5: Use of LHRH Agonists Versus Antagonists in Prostate Cancer
EP. 6: Decisions on Choosing LHRH Agonists for Treating Prostate Cancer
EP. 7: Challenges in Treating Nonmetastatic Castration-Resistant Prostate Cancer
EP. 8: Clinical Trials in Nonmetastatic Castration-Resistant Prostate Cancer
EP. 9: FDA-approved Indications for Treatment Versus Use in Current Clinical Trials
EP. 10: Radium-223 Alone and with Other Agents for Prostate Cancer
EP. 11: Immunotherapy and the Abscopal Effect in Treating Metastatic Prostate Cancer
EP. 12: Identifying Bone Progression in Metastatic Prostate Cancer and Treatment Options
EP. 13: PARP Inhibitors in BRCA1/2-mutated Patients in Prostate Cancer
EP. 14: Future of Genetic Testing and Treatment in Prostate Cancer
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making
